Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22185943 | 0.82 | ALDH1A1 (0.73) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL24758640 | 0.74 | ALDH1A1 (0.79) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL31529425 | 0.73 | EPHX2 (0.69) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL31276295 | 0.72 | EPHX2 (0.72) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL19966024 | 0.71 | EPHX2 (0.77) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL31275669 | 0.71 | EPHX2 (0.75) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL17457691 | 0.69 | ALDH1A1 (0.61) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL22605536 | 0.69 | ALDH1A1 (0.49) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL18250772 | 0.69 | ALDH1A1 (1.00) | ALDH1A1EPHX2MEN1KMT2ACYP3A4 | |
| SCHEMBL18772398 | 0.68 | EPHX2 (0.47) | ALDH1A1EPHX2SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3618833-B1 | TRIPARTITE ANDROGEN RECEPTOR ELIMINATORS, METHODS AND USES THEREOF | SPG THERAPEUTICS INC (US) | 2022-01-19 | — | — | EP | disclosed |